Combined amphotericin B-flucytosine therapy in Aspergillus pneumonia
S. D. Codish, J. S. Tobias and M. Hannigan
The incidence of aspergillosis is increasing while the prognosis remains
dismal. Standard single-drug therapy with amphotericin B offers
unacceptably low cure rates. A patient with Aspergillus pneumonia was
treated with a synergistic combination of amphotericin B and flucytosine. A
prompt clinical response and progressive resolution of the infection were
observed. Combination therapy appeared to decrease the dose of amphotericin
B needed for effective therapy. It may provide improved results with
decreased toxic effects.
